Jazz Pharmaceuticals (JAZZ) Q4 FY25 earnings call

Jazz Pharmaceuticals delivered record financial performance in Q4 and full-year 2025, driven by strong growth in Xywav, Epidiolex, and the successful launch of Modeyso. The company is sharpening its strategic focus on rare disease, leveraging its proven capabilities and pursuing business development opportunities to drive durable growth. While facing evolving competitive dynamics in the sleep market, Jazz remains confident in its differentiated product portfolio and robust pipeline.